Evidence map›Paper›PMID 23732030›Full record

ArticleObstetrics and gynecology clinics of North America2013

Screening adolescents and young women.

Lori A Boardman, Katina Robison

Abstract read
In one paragraph

Article in Obstetrics and gynecology clinics of North America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lori A BoardmanDepartment of Clinical Sciences, University of Central Florida College of Medicine, Orlando, FL 32827, USA. Lori.Boardman@ucf.edu
Katina Robison

Funding

NICHD NIH HHS L30 HD070361
6 · The paper itself

Abstract

Recent guidelines from multiple organizations stress screening initiation no earlier than the age of 21 years and increased screening intervals for women aged 21 to 29 years. Primary prevention with human papillomavirus vaccination has the potential to significantly affect the development of high-grade cervical lesions, including cancer, and will likely affect screening guidelines in the future.

Indexed as

AdolescentAdultChildColposcopyConsensusDeveloping CountriesFemaleHumansMass ScreeningPapanicolaou TestPapillomavirus InfectionsPapillomavirus VaccinesPractice Guidelines as TopicSexually Transmitted DiseasesUterine Cervical DysplasiaUterine Cervical NeoplasmsPapillomavirus Vaccines

Identifiers

PMID23732030
PMCPMC3672857

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.